Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
BioSpace6d
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...
Reuters6d
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Patients on the once-weekly 7.2 milligram dose of Novo's drug for 72 weeks lowered their weight by 20.7% during the trial, compared with 17.5% for the 2.4 milligram dose and 2.4% for the placebo.